Drug intelligence / Profile preview

travoprost + tears natural

Development stage: Unknown
Lead developer: Alcon
Modality: Small Molecules
Administration: Ophthalmic

Overview

This appears to be a combination of travoprost (a prostaglandin analog used to treat increased intraocular pressure) and an artificial tear product. Travoprost works by enhancing the egress of aqueous humor through both the uveoscleral and trabecular outflow channels, effectively lowering intraocular pressure. It is primarily used to treat open-angle glaucoma and ocular hypertension. The typical dosage is one drop in the affected eye(s) once daily in the evening.

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on travoprost + tears natural.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on travoprost + tears natural.

Explore the full profile